ATE375401T1 - Vaccinia virus für diagnose und behandlung von tumoren - Google Patents

Vaccinia virus für diagnose und behandlung von tumoren

Info

Publication number
ATE375401T1
ATE375401T1 AT02794632T AT02794632T ATE375401T1 AT E375401 T1 ATE375401 T1 AT E375401T1 AT 02794632 T AT02794632 T AT 02794632T AT 02794632 T AT02794632 T AT 02794632T AT E375401 T1 ATE375401 T1 AT E375401T1
Authority
AT
Austria
Prior art keywords
protein
microorganism
tumors
diagnosis
tumor
Prior art date
Application number
AT02794632T
Other languages
English (en)
Inventor
Aladar Szalay
Yong Yu
Shahrokh Shabahang
Tatyana Timiryasova
Original Assignee
Genelux Corp
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Priority claimed from EP01118417A external-priority patent/EP1281772A1/de
Application filed by Genelux Corp filed Critical Genelux Corp
Application granted granted Critical
Publication of ATE375401T1 publication Critical patent/ATE375401T1/de

Links

Classifications

    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12Q—MEASURING OR TESTING PROCESSES INVOLVING ENZYMES, NUCLEIC ACIDS OR MICROORGANISMS; COMPOSITIONS OR TEST PAPERS THEREFOR; PROCESSES OF PREPARING SUCH COMPOSITIONS; CONDITION-RESPONSIVE CONTROL IN MICROBIOLOGICAL OR ENZYMOLOGICAL PROCESSES
    • C12Q1/00—Measuring or testing processes involving enzymes, nucleic acids or microorganisms; Compositions therefor; Processes of preparing such compositions
    • C12Q1/02—Measuring or testing processes involving enzymes, nucleic acids or microorganisms; Compositions therefor; Processes of preparing such compositions involving viable microorganisms
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K49/00—Preparations for testing in vivo
    • A61K49/001—Preparation for luminescence or biological staining
    • A61K49/0013—Luminescence
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K38/00—Medicinal preparations containing peptides
    • A61K38/16—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof
    • A61K38/17—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans
    • A61K38/18—Growth factors; Growth regulators
    • A61K38/1841—Transforming growth factor [TGF]
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K38/00—Medicinal preparations containing peptides
    • A61K38/16—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof
    • A61K38/17—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans
    • A61K38/39—Connective tissue peptides, e.g. collagen, elastin, laminin, fibronectin, vitronectin, cold insoluble globulin [CIG]
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K49/00—Preparations for testing in vivo
    • A61K49/001—Preparation for luminescence or biological staining
    • A61K49/0013—Luminescence
    • A61K49/0017—Fluorescence in vivo
    • A61K49/0019—Fluorescence in vivo characterised by the fluorescent group, e.g. oligomeric, polymeric or dendritic molecules
    • A61K49/0045—Fluorescence in vivo characterised by the fluorescent group, e.g. oligomeric, polymeric or dendritic molecules the fluorescent agent being a peptide or protein used for imaging or diagnosis in vivo
    • A61K49/0047—Green fluorescent protein [GFP]
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K49/00—Preparations for testing in vivo
    • A61K49/001—Preparation for luminescence or biological staining
    • A61K49/0063—Preparation for luminescence or biological staining characterised by a special physical or galenical form, e.g. emulsions, microspheres
    • A61K49/0069—Preparation for luminescence or biological staining characterised by a special physical or galenical form, e.g. emulsions, microspheres the agent being in a particular physical galenical form
    • A61K49/0097—Cells, viruses, ghosts, red blood cells, viral vectors, used for imaging or diagnosis in vivo
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K49/00—Preparations for testing in vivo
    • A61K49/06—Nuclear magnetic resonance [NMR] contrast preparations; Magnetic resonance imaging [MRI] contrast preparations
    • A61K49/18—Nuclear magnetic resonance [NMR] contrast preparations; Magnetic resonance imaging [MRI] contrast preparations characterised by a special physical form, e.g. emulsions, microcapsules, liposomes
    • A61K49/1896—Nuclear magnetic resonance [NMR] contrast preparations; Magnetic resonance imaging [MRI] contrast preparations characterised by a special physical form, e.g. emulsions, microcapsules, liposomes not provided for elsewhere, e.g. cells, viruses, ghosts, red blood cells, virus capsides
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P35/00—Antineoplastic agents
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K14/00—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof
    • C07K14/435—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans
    • C07K14/475—Growth factors; Growth regulators
    • C07K14/495—Transforming growth factor [TGF]
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K14/00—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof
    • C07K14/435—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans
    • C07K14/78—Connective tissue peptides, e.g. collagen, elastin, laminin, fibronectin, vitronectin or cold insoluble globulin [CIG]
    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12Q—MEASURING OR TESTING PROCESSES INVOLVING ENZYMES, NUCLEIC ACIDS OR MICROORGANISMS; COMPOSITIONS OR TEST PAPERS THEREFOR; PROCESSES OF PREPARING SUCH COMPOSITIONS; CONDITION-RESPONSIVE CONTROL IN MICROBIOLOGICAL OR ENZYMOLOGICAL PROCESSES
    • C12Q1/00—Measuring or testing processes involving enzymes, nucleic acids or microorganisms; Compositions therefor; Processes of preparing such compositions
    • C12Q1/66—Measuring or testing processes involving enzymes, nucleic acids or microorganisms; Compositions therefor; Processes of preparing such compositions involving luciferase
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K2319/00—Fusion polypeptide
    • C07K2319/55—Fusion polypeptide containing a fusion with a toxin, e.g. diphteria toxin
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K2319/00—Fusion polypeptide
    • C07K2319/60—Fusion polypeptide containing spectroscopic/fluorescent detection, e.g. green fluorescent protein [GFP]
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K2319/00—Fusion polypeptide
    • C07K2319/61—Fusion polypeptide containing an enzyme fusion for detection (lacZ, luciferase)
    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
    • C12N2710/00—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA dsDNA viruses
    • C12N2710/00011—Details
    • C12N2710/24011—Poxviridae
    • C12N2710/24111—Orthopoxvirus, e.g. vaccinia virus, variola
    • C12N2710/24132—Use of virus as therapeutic agent, other than vaccine, e.g. as cytolytic agent

Landscapes

  • Health & Medical Sciences (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Chemical & Material Sciences (AREA)
  • Engineering & Computer Science (AREA)
  • Organic Chemistry (AREA)
  • General Health & Medical Sciences (AREA)
  • Zoology (AREA)
  • Proteomics, Peptides & Aminoacids (AREA)
  • Molecular Biology (AREA)
  • Veterinary Medicine (AREA)
  • Public Health (AREA)
  • Animal Behavior & Ethology (AREA)
  • Epidemiology (AREA)
  • Biomedical Technology (AREA)
  • Wood Science & Technology (AREA)
  • Immunology (AREA)
  • Medicinal Chemistry (AREA)
  • Genetics & Genomics (AREA)
  • Biophysics (AREA)
  • Biochemistry (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Gastroenterology & Hepatology (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Radiology & Medical Imaging (AREA)
  • General Engineering & Computer Science (AREA)
  • Physics & Mathematics (AREA)
  • Analytical Chemistry (AREA)
  • Microbiology (AREA)
  • Biotechnology (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Hematology (AREA)
  • Pathology (AREA)
  • Virology (AREA)
  • Toxicology (AREA)
  • General Chemical & Material Sciences (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • Medicines Containing Antibodies Or Antigens For Use As Internal Diagnostic Agents (AREA)
  • Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
  • Medicines Containing Material From Animals Or Micro-Organisms (AREA)
  • Micro-Organisms Or Cultivation Processes Thereof (AREA)
AT02794632T 2001-07-31 2002-07-31 Vaccinia virus für diagnose und behandlung von tumoren ATE375401T1 (de)

Applications Claiming Priority (2)

Application Number Priority Date Filing Date Title
EP01118417A EP1281772A1 (de) 2001-07-31 2001-07-31 Lichtemittierende Mikroorganismen und Zellen zum Nachweis und zur Therapie von Krebs
EP01125911A EP1281767A3 (de) 2001-07-31 2001-10-30 Lichtausstrahlende Mikroorganismen und Zellen für die Diagnose und Therapie von Tumoren

Publications (1)

Publication Number Publication Date
ATE375401T1 true ATE375401T1 (de) 2007-10-15

Family

ID=26076668

Family Applications (2)

Application Number Title Priority Date Filing Date
AT07018460T ATE452205T1 (de) 2001-07-31 2002-07-31 Livp stamm von vaccinia-virus zur diagnose und behandlung von tumoren
AT02794632T ATE375401T1 (de) 2001-07-31 2002-07-31 Vaccinia virus für diagnose und behandlung von tumoren

Family Applications Before (1)

Application Number Title Priority Date Filing Date
AT07018460T ATE452205T1 (de) 2001-07-31 2002-07-31 Livp stamm von vaccinia-virus zur diagnose und behandlung von tumoren

Country Status (17)

Country Link
US (7) US20030059400A1 (de)
EP (2) EP1281767A3 (de)
KR (3) KR20040054668A (de)
CN (1) CN100415897C (de)
AT (2) ATE452205T1 (de)
BR (1) BR0211546A (de)
CA (1) CA2456055C (de)
DE (3) DE60234793D1 (de)
IL (1) IL160052A0 (de)
MX (1) MXPA04000882A (de)
NO (1) NO20040428L (de)
NZ (1) NZ530818A (de)
PL (1) PL374326A1 (de)
RU (1) RU2357754C2 (de)
SG (1) SG168404A1 (de)
TR (1) TR200400149T2 (de)
WO (1) WO2003014380A2 (de)

Families Citing this family (80)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
CN1253551C (zh) * 1997-09-10 2006-04-26 维昂药品公司 减毒的遗传修饰肿瘤靶向细菌
US6080849A (en) * 1997-09-10 2000-06-27 Vion Pharmaceuticals, Inc. Genetically modified tumor-targeted bacteria with reduced virulence
US6962696B1 (en) * 1999-10-04 2005-11-08 Vion Pharmaceuticals Inc. Compositions and methods for tumor-targeted delivery of effector molecules
EP1281767A3 (de) 2001-07-31 2003-05-28 Aladar A. Szalay Lichtausstrahlende Mikroorganismen und Zellen für die Diagnose und Therapie von Tumoren
KR101142380B1 (ko) * 2001-12-31 2012-05-18 안티캔서, 인코포레이티드 박테리아 종양 치료의 모니터링 시스템
US20030228261A1 (en) * 2002-06-05 2003-12-11 Aladar Szalay Light emitting microorganisms and cells for diagnosis and therapy of diseases associated with wounded or inflamed tissue
EP1369491A1 (de) 2002-06-05 2003-12-10 Aladar A. Szalay Lichtemittierende Mikroorganismen und Zellen für die Diagnose und Therapie von Krankheiten assoziiert mit Wunden oder entzündetem Gewebe
WO2004038039A2 (en) * 2002-10-21 2004-05-06 The Regents Of The University Of California Optical imagiong of renilla luciferase reporter gene expression in living organisms
US20050008618A1 (en) * 2003-02-27 2005-01-13 Howard Kaufman Composition for delivering an agent to a target cell and uses thereof
RU2376371C2 (ru) * 2003-06-18 2009-12-20 Дженелюкс Корпорейшн Модифицированные рекомбинантные вакцинирующие вирусы и другие микроорганизмы и их применение
US7155274B1 (en) 2003-11-21 2006-12-26 Imaging Diagnostic Systems, Inc. Optical computed tomography scanner for small laboratory animals
US8501198B2 (en) * 2004-06-07 2013-08-06 Qu Biologics Inc. Tissue targeted antigenic activation of the immune response to treat cancers
US9107864B2 (en) 2004-06-07 2015-08-18 Qu Biologics Inc. Tissue targeted antigenic activation of the immune response to treat cancers
CA2526327C (en) * 2004-11-09 2014-01-07 Institut National D'optique Device for transmitting multiple optically-encoded stimulation signals to multiple cell locations
CN101208256B (zh) 2005-04-25 2013-09-18 高级技术材料公司 具有空检测能力的基于衬里的液体储存和分配系统
US20070231833A1 (en) * 2005-05-23 2007-10-04 Arcidiacono Steven M Labeled antimicrobial peptides and method of using the same to detect microorganisms of interest
KR20110017462A (ko) 2005-06-06 2011-02-21 어드밴스드 테크놀러지 머티리얼즈, 인코포레이티드 유체 저장 및 분배 시스템과 프로세스
TW200819540A (en) 2006-07-11 2008-05-01 Genelux Corp Methods and compositions for detection of microorganisms and cells and treatment of diseases and disorders
US20080124355A1 (en) 2006-09-22 2008-05-29 David Gordon Bermudes Live bacterial vaccines for viral infection prophylaxis or treatment
WO2008100292A2 (en) 2006-10-16 2008-08-21 Genelux Corporation Modified vaccinia virus strains for use in diagnostic and therapeutic methods
WO2008150496A2 (en) * 2007-05-31 2008-12-11 Genelux Corporation Assay for sensitivity to chemotherapeutic agents
WO2008156655A2 (en) 2007-06-15 2008-12-24 Genelux Corporation Vaccinia virus vectors encoding a sodium-dependent transporter protein for imaging and/or treatment of tumors
EP2173368A1 (de) * 2007-07-18 2010-04-14 Genelux Corporation Verwendung eines chemotherapeutischen mittels zur herstellung eines medikaments zur behandlung oder linderung einer mit einer onkolytischen virentherapie verbundenen unerwünschten nebenwirkung
GB0718957D0 (en) * 2007-09-28 2007-11-07 Ge Healthcare Ltd Optical imaging agents
WO2009032160A2 (en) * 2007-08-28 2009-03-12 Massachusetts Institute Of Technology Metalloprotein mri contrast agents and related methods
US20090068114A1 (en) * 2007-09-07 2009-03-12 Yousef Haik Noninvasive Thermometry Monitoring System
US20090068112A1 (en) * 2007-09-11 2009-03-12 Yousef Haik Magnetic Nanoparticles for Imaging
WO2009054996A2 (en) 2007-10-25 2009-04-30 Genelux Corporation Systems and methods for viral therapy
US20090176260A1 (en) * 2007-12-04 2009-07-09 Joseph Ching-Ming Wu Double-fusion human embryonic stem cells, methods of making double-fusion human embryonic stem cells, triple-fusion human embryonic stem cells, methods of making triple-fusion human embryonic stem cells, and methods of monitoring double-fusion human embryonic stem cells and triple-fusion human embryonic stem cells
WO2009126189A1 (en) 2008-01-11 2009-10-15 Genelux Corporation Methods and compositions for detection of bacteria and treatment of diseases and disorders
US20120052003A9 (en) * 2008-05-16 2012-03-01 Szalay Aladar A Microorganisms for preventing and treating neoplasms accompanying cellular therapy
US8647642B2 (en) 2008-09-18 2014-02-11 Aviex Technologies, Llc Live bacterial vaccines resistant to carbon dioxide (CO2), acidic PH and/or osmolarity for viral infection prophylaxis or treatment
US8241623B1 (en) 2009-02-09 2012-08-14 David Bermudes Protease sensitivity expression system
GB2472790A (en) * 2009-08-18 2011-02-23 Laurence Christian Hayes Dermatological preparations comprising microbes.
US8524220B1 (en) 2010-02-09 2013-09-03 David Gordon Bermudes Protease inhibitor: protease sensitivity expression system composition and methods improving the therapeutic activity and specificity of proteins delivered by bacteria
US8771669B1 (en) 2010-02-09 2014-07-08 David Gordon Bermudes Immunization and/or treatment of parasites and infectious agents by live bacteria
US9597379B1 (en) 2010-02-09 2017-03-21 David Gordon Bermudes Protease inhibitor combination with therapeutic proteins including antibodies
US10357577B2 (en) 2010-07-16 2019-07-23 Auckland Uniservices Limited Bacterial nitroreductase enzymes and methods relating thereto
EP4324526A3 (de) 2010-07-26 2024-05-22 Qu Biologics Inc. Immunogene entzündungshemmende zusammensetzungen
US20130243741A1 (en) * 2010-09-21 2013-09-19 Kansas State University Research Foundation Renilla/gaussia transfected cells as a light source for in-situ photodynamic therapy of cancer
CA2836299A1 (en) 2011-04-15 2012-10-18 Genelux Corporation Clonal strains of attenuated vaccinia viruses and methods of use thereof
US8859256B2 (en) 2011-10-05 2014-10-14 Genelux Corporation Method for detecting replication or colonization of a biological therapeutic
US8956873B2 (en) 2012-01-13 2015-02-17 Bell Biosystems, Inc. Host cells with artificial endosymbionts
US9023612B2 (en) 2012-01-13 2015-05-05 Bell Biosystems, Inc. Eukaryotic cells with artificial endosymbionts for multimodal detection
US10076579B2 (en) 2012-01-13 2018-09-18 Bell Biosystems, Inc. Host cells with artificial endosymbionts
US8828681B2 (en) 2012-01-13 2014-09-09 Bell Biosystems, Inc. Host cells with artificial endosymbionts
CN104245924B (zh) * 2012-03-06 2020-05-01 塞莱克特生物疗法有限公司 用于选择抗细胞凋亡信号传导细胞的装置和方法及其用途
US20140087362A1 (en) 2012-03-16 2014-03-27 Aladar A. Szalay Methods for assessing effectiveness and monitoring oncolytic virus treatment
US20130280170A1 (en) 2012-04-20 2013-10-24 Aladar A. Szalay Imaging methods for oncolytic virus therapy
US20140140959A1 (en) 2012-10-05 2014-05-22 Aladar A. Szalay Energy Absorbing-Based Diagnostic and Therapeutic Methods Employing Nucleic Acid Molecules Encoding Chromophore-Producing Enzymes
US9593339B1 (en) 2013-02-14 2017-03-14 David Gordon Bermudes Bacteria carrying bacteriophage and protease inhibitors for the treatment of disorders and methods of treatment
WO2014145785A1 (en) 2013-03-15 2014-09-18 Bell Biosystems, Llc Host cells with artificial endosymbionts
GB201310917D0 (en) * 2013-06-19 2013-07-31 Cancer Res Inst Royal Vaccinia virus for gene-directed enzyme prodrug therapy
SG11201601488VA (en) * 2013-09-03 2016-03-30 Bell Biosystems Inc Host cell modification with artificial endosymbionts
WO2015103438A2 (en) 2014-01-02 2015-07-09 Genelux Corporation Oncolytic virus adjunct therapy with agents that increase virus infectivity
EP3105323A4 (de) * 2014-02-13 2017-10-25 Bell Biosystems, Inc. Systeme zur herstellung von wirtszellen mit künstlichen endosymbionten
US9737592B1 (en) 2014-02-14 2017-08-22 David Gordon Bermudes Topical and orally administered protease inhibitors and bacterial vectors for the treatment of disorders and methods of treatment
CA2947631A1 (en) 2014-05-02 2015-11-05 Qu Biologics Inc. Anti-microbial immunomodulation
CN104162175B (zh) * 2014-06-18 2017-02-01 东华大学 功能化的基于树状大分子的spect‑ct双模态成像造影剂及其制备方法
AU2015289512B2 (en) 2014-07-17 2018-08-30 The Board Of Trustees Of Western Michigan University Composition for treating cancerous cells and a method therefor
US9616114B1 (en) 2014-09-18 2017-04-11 David Gordon Bermudes Modified bacteria having improved pharmacokinetics and tumor colonization enhancing antitumor activity
US10676723B2 (en) 2015-05-11 2020-06-09 David Gordon Bermudes Chimeric protein toxins for expression by therapeutic bacteria
US11129906B1 (en) 2016-12-07 2021-09-28 David Gordon Bermudes Chimeric protein toxins for expression by therapeutic bacteria
US11180535B1 (en) 2016-12-07 2021-11-23 David Gordon Bermudes Saccharide binding, tumor penetration, and cytotoxic antitumor chimeric peptides from therapeutic bacteria
CN107365799A (zh) * 2017-08-08 2017-11-21 四川省肿瘤医院 Sod2慢病毒载体、构建方法及其在靶向性辐射防护和肿瘤增敏中的应用
AU2019282239B2 (en) 2018-06-04 2024-06-06 Calidi Biotherapeutics (Nevada), Inc. Cell-based vehicles for potentiation of viral therapy
US11505782B2 (en) 2018-06-04 2022-11-22 Calidi Biotherapeutics, Inc. Cell-based vehicles for potentiation of viral therapy
EP3844276A2 (de) 2018-08-28 2021-07-07 Actym Therapeutics, Inc. Manipulierte immunstimulierende bakterienstämme und verwendungen davon
EP3876951A1 (de) 2018-11-06 2021-09-15 Calidi Biotherapeutics, Inc. Verbesserte systeme für zellvermittelte onkolytische virustherapie
SG11202108459QA (en) 2019-02-27 2021-09-29 Actym Therapeutics Inc Immunostimulatory bacteria engineered to colonize tumors, tumor-resident immune cells, and the tumor microenvironment
US12024709B2 (en) 2019-02-27 2024-07-02 Actym Therapeutics, Inc. Immunostimulatory bacteria engineered to colonize tumors, tumor-resident immune cells, and the tumor microenvironment
US11471497B1 (en) 2019-03-13 2022-10-18 David Gordon Bermudes Copper chelation therapeutics
GB201914096D0 (en) * 2019-09-30 2019-11-13 Rna Guardian Ltd Cancer Biomarker
US12285437B2 (en) 2019-10-30 2025-04-29 The Research Foundation For The State University Of New York Reversing the undesirable pH-profile of doxorubicin via activation of a disubstituted maleamic acid prodrug at tumor acidity
US10973908B1 (en) 2020-05-14 2021-04-13 David Gordon Bermudes Expression of SARS-CoV-2 spike protein receptor binding domain in attenuated salmonella as a vaccine
US12537071B1 (en) 2020-07-22 2026-01-27 David Gordon Bermudes Bacteria having boolean control pathways expressing therapeutic proteins including immunotherapeutic cytotoxins
US11297054B1 (en) * 2020-10-06 2022-04-05 International Business Machines Corporation Authentication system(s) with multiple authentication modes using one-time passwords of increased security
RU2755010C1 (ru) * 2021-01-26 2021-09-09 Федеральное государственное бюджетное научное учреждение "Томский национальный исследовательский медицинский центр" Российской академии наук ("Томский НИМЦ") Способ диагностики рака ободочной кишки
WO2025184411A1 (en) 2024-02-27 2025-09-04 Calidi Biotherapeutics (Nevada), Inc. Serum-resistant eev viruses and uses thereof
CN118064333B (zh) * 2024-04-18 2024-07-05 青岛诺和诺康生物科技有限公司 一株唾液联合乳杆菌及其在制备改善皮肤色泽产品中的应用

Family Cites Families (128)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US31681A (en) * 1861-03-12 Puhchifg-machine
US228330A (en) * 1880-06-01 Advertising checker-board
US165465A (en) * 1875-07-13 Improvement in paper-weights
US9015A (en) * 1852-06-15 Manufacture of granular fuel from brush-wood and twigs
US886906A (en) * 1907-05-20 1908-05-05 Katie Putnam Emery Cherry-pitter.
JPS542336A (en) * 1977-06-06 1979-01-09 Meiji Seika Kaisha Ltd Preventive and remedy for viral diseases
EP0037441B1 (de) 1980-03-10 1984-05-09 Seiji Arakawa Pharmazeutische Zusammensetzungen zur zellulären Immunopotentialisation und als Antitumor-Mittel, Verfahren zu ihrer Herstellung und der darin verwendete Mikroorganismus
US4315914A (en) * 1980-04-04 1982-02-16 Seiji Arakawa Pharmaceutical compositions useful as cellular immunopotentiator and antitumor agent and process for production thereof
US4442203A (en) * 1981-06-30 1984-04-10 Massachusetts Institute Of Technology Gene amplification assay for detecting tumor promoters
US5155020A (en) * 1989-03-08 1992-10-13 Health Research Inc. Recombinant poxvirus host range selection system
US4603112A (en) * 1981-12-24 1986-07-29 Health Research, Incorporated Modified vaccinia virus
US4769330A (en) * 1981-12-24 1988-09-06 Health Research, Incorporated Modified vaccinia virus and methods for making and using the same
US5378457A (en) * 1981-12-24 1995-01-03 Virogenetics Corporation Interferon sensitive recombinant poxvirus vaccine
US4722848A (en) * 1982-12-08 1988-02-02 Health Research, Incorporated Method for immunizing animals with synthetically modified vaccinia virus
US5110587A (en) * 1981-12-24 1992-05-05 Health Research, Incorporated Immunogenic composition comprising synthetically modified vaccinia virus
US5364773A (en) * 1991-03-07 1994-11-15 Virogenetics Corporation Genetically engineered vaccine strain
US5833975A (en) * 1989-03-08 1998-11-10 Virogenetics Corporation Canarypox virus expressing cytokine and/or tumor-associated antigen DNA sequence
US4778759A (en) * 1982-07-09 1988-10-18 Boyce, Thompson Institute For Plant Research, Inc. Genetic engineering in cyanobacteria
US7045313B1 (en) * 1982-11-30 2006-05-16 The United States Of America As Represented By The Department Of Health And Human Services Recombinant vaccinia virus containing a chimeric gene having foreign DNA flanked by vaccinia regulatory DNA
US5221623A (en) * 1986-07-22 1993-06-22 Boyce Thompson Institute For Plant Research, Inc. Use of bacterial luciferase structural genes for cloning and monitoring gene expression in microorganisms and for tagging and identification of genetically engineered organisms
US5866136A (en) * 1986-08-01 1999-02-02 Commonwealth Scientific And Industrial Organisation Recombinant vaccine
US6007806A (en) 1986-08-13 1999-12-28 Transgene S.A. Expression of a tumor-specific antigen by a recombinant vector virus and use thereof in preventive or curative treatment of the corresponding tumor
US5283187A (en) * 1987-11-17 1994-02-01 Brown University Research Foundation Cell culture-containing tubular capsule produced by co-extrusion
DE68919846T2 (de) * 1988-02-12 1995-07-06 Commw Scient Ind Res Org Poxvirus-vektoren.
US5650148A (en) * 1988-12-15 1997-07-22 The Regents Of The University Of California Method of grafting genetically modified cells to treat defects, disease or damage of the central nervous system
DE69032841T2 (de) 1989-01-23 1999-05-12 Chiron Corp., Emeryville, Calif. Rekombinante zellen für therapien von infektionen und hyperprolieferative störungen und deren herstellung
WO1991007989A1 (en) * 1989-11-28 1991-06-13 Universite Laval A method of inactivating human immunodeficiency virus
US5618531A (en) * 1990-10-19 1997-04-08 New York University Method for increasing the viability of cells which are administered to the brain or spinal cord
US5830702A (en) * 1990-10-31 1998-11-03 The Trustees Of The University Of Pennsylvania Live, recombinant listeria monocytogenes and production of cytotoxic T-cell response
US5863542A (en) * 1991-03-07 1999-01-26 Virogenetics Corporation Recombinant attenuated ALVAC canaryopox virus containing heterologous HIV or SIV inserts
US5212082A (en) * 1991-03-13 1993-05-18 New York University Genetically modified tyrosine hydroxylase and uses thereof
HK1001832A1 (en) 1991-04-25 1998-07-10 Brown University Research Foundation Implantable biocompatible immunoisolatory vehicle for delivery of selected therapeutic products
US5800829A (en) 1991-04-25 1998-09-01 Brown University Research Foundation Methods for coextruding immunoisolatory implantable vehicles with a biocompatible jacket and a biocompatible matrix core
US5718902A (en) * 1991-06-17 1998-02-17 The Regents Of The University Of California Double recombinant vaccinia virus vaccines
US5411860A (en) * 1992-04-07 1995-05-02 The Johns Hopkins University Amplification of human MDM2 gene in human tumors
US5762959A (en) * 1992-05-29 1998-06-09 Vivorx, Inc. Microencapsulation of cells
JP4098355B2 (ja) * 1993-08-12 2008-06-11 ニューロテック ユーエスエー， インコーポレイテッド 遺伝的に改変された細胞を含む生体適合性免疫隔離カプセル
US6491905B1 (en) 1993-09-14 2002-12-10 The Uab Research Foundation Recombinant bacterial cells for delivery of PNP to tumor cells
FR2710536B1 (fr) 1993-09-29 1995-12-22 Transgene Sa Usage anti-cancéreux d'un vecteur viral comportant un gène modulateur de la réponse immunitaire et/ou inflammatoire.
US6416754B1 (en) 1994-03-03 2002-07-09 The Board Of Trustees Of The Leland Stanford Junior University Anaerobe targeted enzyme-mediated prodrug therapy
US5550050A (en) * 1994-04-15 1996-08-27 Cytotherapeutics, Inc. Method for implanting encapsulated cells in a host
US6093700A (en) * 1995-05-11 2000-07-25 Thomas Jefferson University Method of inducing an immune response using vaccinia virus recombinants encoding GM-CSF
DE69535288T2 (de) * 1994-05-13 2007-04-05 Thomas Jefferson University Verfahren zur induzierung einer immunantwort mittels rekombinanten vaccinia-viren, die das gm-csf-gen exprimieren
US6455673B1 (en) * 1994-06-08 2002-09-24 President And Fellows Of Harvard College Multi-mutant diphtheria toxin vaccines
US5650135A (en) 1994-07-01 1997-07-22 The Board Of Trustees Of The Leland Stanford Junior University Non-invasive localization of a light-emitting conjugate in a mammal
US6649143B1 (en) 1994-07-01 2003-11-18 The Board Of Trustees Of The Leland Stanford Junior University Non-invasive localization of a light-emitting conjugate in a mammal
US5853717A (en) 1994-07-20 1998-12-29 Cytotherapeutics, Inc. Methods and compositions of growth control for cells encapsulated within bioartificial organs
US5853385A (en) 1994-08-26 1998-12-29 Cytotherapeutics, Inc. Encapsulated PC12 cell transplants for treatment of Parkinson's disease
ES2154738T3 (es) * 1994-10-03 2001-04-16 Us Gov Health & Human Serv Composicion que comprende un virus recombinante que expresa un antigeno y un virus recombinante que expresa una molecula inmunoestimuladora.
US6045802A (en) * 1994-10-03 2000-04-04 The United States Of America As Represented By The Secretary Of The Department Of Health And Human Services Enhanced immune response to an antigen by a composition of a recombinant virus expressing the antigen with a recombinant virus expressing an immunostimulatory molecule
US5693533A (en) 1994-12-07 1997-12-02 The Goodwin Institue For Cancer Research Human breast carcinoma cell line capable of production of a spontaneously metastasizing tumor in animals for use in anticancer drug testing
US6150170A (en) 1998-05-03 2000-11-21 University Of Maryland At Baltimore Method for introducing and expressing genes in animal cells, and live invasive bacterial vectors for use in the same
US6503703B1 (en) * 1995-05-19 2003-01-07 Mount Sinai School Of Medicine Of New York University Identification and use of antiviral compounds that inhibit interaction of host cell proteins and viral proteins required for viral replication
US5704910A (en) * 1995-06-05 1998-01-06 Nephros Therapeutics, Inc. Implantable device and use therefor
US6190657B1 (en) * 1995-06-07 2001-02-20 Yale University Vectors for the diagnosis and treatment of solid tumors including melanoma
US5837234A (en) 1995-06-07 1998-11-17 Cytotherapeutics, Inc. Bioartificial organ containing cells encapsulated in a permselective polyether suflfone membrane
US5646298A (en) 1995-06-07 1997-07-08 Procoron, Inc. Cyclopropylindole prodrugs
US20020160970A1 (en) * 1996-04-10 2002-10-31 Gyula Hadlaczky Artificial chromosomes, uses thereof and methods for preparing artificial chromosomes
US6025155A (en) 1996-04-10 2000-02-15 Chromos Molecular Systems, Inc. Artificial chromosomes, uses thereof and methods for preparing artificial chromosomes
US20030033617A1 (en) * 1996-04-10 2003-02-13 Gyula Hadlaczky Artificial chromosomes, uses thereof and methods for preparing artificial chromosomes
US6077697A (en) * 1996-04-10 2000-06-20 Chromos Molecular Systems, Inc. Artificial chromosomes, uses thereof and methods for preparing artificial chromosomes
US5710137A (en) * 1996-08-16 1998-01-20 The Trustees Of Columbia University In The City Of New York Use of a melanoma differentiation associated gene (mda 7) for reversing a cancerous phenotype
US5976796A (en) 1996-10-04 1999-11-02 Loma Linda University Construction and expression of renilla luciferase and green fluorescent protein fusion genes
US5842431A (en) 1997-02-19 1998-12-01 Wu; Chong-Ming Rotating shuttle and presser plate arrangement
US6235968B1 (en) 1997-04-28 2001-05-22 Anticancer, Inc. Metastasis models using green fluorescent protein (GFP) as a marker
US6251384B1 (en) 1997-04-28 2001-06-26 Anticancer, Inc. Metastasis models using green fluorescent protein (GFP) as a marker
US6232523B1 (en) 1997-04-28 2001-05-15 Anticancer, Inc. Metastasis models using green fluorescent protein (GFP) as a marker
US6884414B1 (en) * 1997-04-30 2005-04-26 Mount Sinai School Of Medicine Of New York University Recombinant influenza viruses expressing tumor-associated antigens as antitumor agents
US6265557B1 (en) 1997-05-09 2001-07-24 Loma Linda University Medical Center ABO histo-blood group O alleles of the baboon
US6713284B2 (en) 1997-06-25 2004-03-30 The United States Of America As Represented By The Secretary Of The Army Bacterial superantigen vaccines
US6080849A (en) 1997-09-10 2000-06-27 Vion Pharmaceuticals, Inc. Genetically modified tumor-targeted bacteria with reduced virulence
US20030044384A1 (en) 1997-10-09 2003-03-06 Pro-Virus, Inc. Treatment of neoplasms with viruses
US7780962B2 (en) 1997-10-09 2010-08-24 Wellstat Biologics Corporation Treatment of neoplasms with RNA viruses
US6099848A (en) * 1997-11-18 2000-08-08 The Trustees Of The University Of Pennsylvania Immunogenic compositions comprising DAL/DAT double-mutant, auxotrophic, attenuated strains of Listeria and their methods of use
DE29924318U1 (de) 1999-01-14 2002-09-19 Fleischmann, Wilhelm, Dr.med., 74321 Bietigheim-Bissingen Verbandsmaterial
US6713293B1 (en) 1999-02-08 2004-03-30 Friedrich Grummt Encapsulated cells containing an amplified expression vector as a drug delivery device
US6428968B1 (en) * 1999-03-15 2002-08-06 The Trustees Of The University Of Pennsylvania Combined therapy with a chemotherapeutic agent and an oncolytic virus for killing tumor cells in a subject
US6511967B1 (en) * 1999-04-23 2003-01-28 The General Hospital Corporation Use of an internalizing transferrin receptor to image transgene expression
CA2375189C (en) 1999-05-28 2010-02-09 The Government Of The United States Of America A combined growth factor-deleted and thymidine kinase-deleted vaccinia virus vector
US6627190B2 (en) 1999-07-12 2003-09-30 Saint Louis University Recombinant adenovirus vectors that are replication-competent in tert-expressing cells
US6544781B1 (en) * 1999-07-15 2003-04-08 The General Hospital Corporation Non-defective Epstein-Barr viral vector
CA2384496A1 (en) * 1999-09-08 2001-03-15 Xenogen Corporation Luciferase expression cassettes and methods of use
AU7856100A (en) * 1999-10-04 2001-05-10 Vion Pharmaceuticals, Inc. Methods for treating solid tumors with irradiation and bacteria
WO2001025399A2 (en) * 1999-10-04 2001-04-12 Vion Pharmaceuticals, Inc. Non-invasive tumor imaging by tumor-targeted bacteria
US6589531B1 (en) * 2000-01-21 2003-07-08 The Regents Of The University Of California Recombinant yellow fever virus and method of use thereof
US20010029023A1 (en) * 2000-01-26 2001-10-11 Szalay Aladar A. Method for the evaluation of implantable materials
US6448073B1 (en) 2000-01-28 2002-09-10 Ludwig Institute For Cancer Research Isolated nucleic acid molecules encoding cancer associated antigens, the antigens per se, and uses thereof
EP1294906B1 (de) 2000-03-17 2009-01-21 Anticancer, Inc. Optisches abbildungssystem zur darstellung der genexpression des gesamten körpers und anwendungen
DE10013511A1 (de) * 2000-03-20 2001-10-11 Brand Gmbh & Co Kg Mehrkanal-Pipettiereinrichtung sowie Pipettenschaft dafür
JP4231226B2 (ja) 2000-04-04 2009-02-25 新日本製鐵株式会社 圧延ｈ形鋼の製造方法
CA2341356C (en) 2000-04-14 2011-10-11 Transgene S.A. Poxvirus with targeted infection specificity
JP3642755B2 (ja) 2000-09-21 2005-04-27 純 天野 嫌気性菌を用いた遺伝子治療用医薬
CA2342040C (en) * 2000-09-21 2012-07-10 Kyowa Hakko Kogyo Co., Ltd. Anaerobic bacterium as a drug for cancer gene therapy
US7118740B1 (en) 2000-09-22 2006-10-10 Mayo Foundation For Medical Education And Research Method for limiting the growth of cancer cells using an attenuated measles virus
US20040091995A1 (en) * 2001-06-15 2004-05-13 Jeffrey Schlom Recombinant non-replicating virus expressing gm-csf and uses thereof to enhance immune responses
JP2005520781A (ja) 2001-07-09 2005-07-14 アンチキャンサー インコーポレーテッド 蛍光タンパク質をマーカーとして用いた感染の画像化
EP1409653A4 (de) 2001-07-23 2006-05-03 Onyx Pharma Inc In menschlichen zielkrebszellen selektiv replizierende virusmutanten
EP1281772A1 (de) 2001-07-31 2003-02-05 Aladar A. Szalay Lichtemittierende Mikroorganismen und Zellen zum Nachweis und zur Therapie von Krebs
EP1281767A3 (de) 2001-07-31 2003-05-28 Aladar A. Szalay Lichtausstrahlende Mikroorganismen und Zellen für die Diagnose und Therapie von Tumoren
US20030198627A1 (en) 2001-09-01 2003-10-23 Gert-Jan Arts siRNA knockout assay method and constructs
AU2002350235A1 (en) 2001-11-21 2003-06-10 The Johns Hopkins University Combination bacteriolytic therapy for the treatment of tumors
AU2002347317B2 (en) * 2001-11-30 2008-06-26 Isis Innovation Limited Vaccine
KR101142380B1 (ko) 2001-12-31 2012-05-18 안티캔서, 인코포레이티드 박테리아 종양 치료의 모니터링 시스템
JP2005531507A (ja) 2002-03-02 2005-10-20 ザ ボード オブ リージェンツ，ザ ユニバーシティ オブ テキサス システム ストローマ細胞前駆体による抗癌物質の局所的な産生および／または送達方法
WO2003078640A2 (en) 2002-03-15 2003-09-25 Baxter International Inc. Recombinant drug-sensitive vaccinia virus as smallpox vaccine
US20030213007A1 (en) 2002-03-27 2003-11-13 Slattery Charles Wilbur Human milk produced by human mammary tissue implanted in non-human host animals and uses thereof
US20060147420A1 (en) 2004-03-10 2006-07-06 Juan Fueyo Oncolytic adenovirus armed with therapeutic genes
CA2486980A1 (en) 2002-05-29 2003-12-11 The Regents Of The University Of California Attenuated listeria spp. and methods for using the same
US20030228261A1 (en) 2002-06-05 2003-12-11 Aladar Szalay Light emitting microorganisms and cells for diagnosis and therapy of diseases associated with wounded or inflamed tissue
EP1369491A1 (de) 2002-06-05 2003-12-10 Aladar A. Szalay Lichtemittierende Mikroorganismen und Zellen für die Diagnose und Therapie von Krankheiten assoziiert mit Wunden oder entzündetem Gewebe
EP2269618A1 (de) * 2002-08-12 2011-01-05 Jennerex Biotherapeutics ULC Ein onkolytisches Vaccinia-Virus zur Verwendung in Kombination mit Chemotherapie zur Behandlung von Krebs
WO2004044175A2 (en) 2002-11-12 2004-05-27 Anticancer, Inc. Fluorescence guided cell capture
EP1526185B1 (de) 2003-10-22 2012-09-12 Genelux Corporation Verwendung von Mikroorganismen oder Zellen zur Autoimmunisierung gegen Tumoren
RU2376371C2 (ru) 2003-06-18 2009-12-20 Дженелюкс Корпорейшн Модифицированные рекомбинантные вакцинирующие вирусы и другие микроорганизмы и их применение
DE60329594D1 (de) 2003-08-14 2009-11-19 Genelux Corp Methode zur Herstellung eines Polypeptides, einer RNA oder einer anderen Verbindung in Tumorgewebe
WO2005057488A2 (en) 2003-12-03 2005-06-23 Anticancer, Inc. Modular system for multi-color, whole body fluorescence imaging
US20080038204A1 (en) 2004-01-26 2008-02-14 Meng Yang Whole Body Imaging Using Portable Observation Systems
WO2007075879A2 (en) 2005-12-22 2007-07-05 Memorial Sloan-Kettering Cancer Center Method for detection of cancer cells using virus
TW200819540A (en) * 2006-07-11 2008-05-01 Genelux Corp Methods and compositions for detection of microorganisms and cells and treatment of diseases and disorders
WO2008100292A2 (en) 2006-10-16 2008-08-21 Genelux Corporation Modified vaccinia virus strains for use in diagnostic and therapeutic methods
WO2008150496A2 (en) * 2007-05-31 2008-12-11 Genelux Corporation Assay for sensitivity to chemotherapeutic agents
WO2008156655A2 (en) * 2007-06-15 2008-12-24 Genelux Corporation Vaccinia virus vectors encoding a sodium-dependent transporter protein for imaging and/or treatment of tumors
EP2173368A1 (de) * 2007-07-18 2010-04-14 Genelux Corporation Verwendung eines chemotherapeutischen mittels zur herstellung eines medikaments zur behandlung oder linderung einer mit einer onkolytischen virentherapie verbundenen unerwünschten nebenwirkung
WO2009054996A2 (en) * 2007-10-25 2009-04-30 Genelux Corporation Systems and methods for viral therapy
WO2009126189A1 (en) 2008-01-11 2009-10-15 Genelux Corporation Methods and compositions for detection of bacteria and treatment of diseases and disorders
US20120052003A9 (en) 2008-05-16 2012-03-01 Szalay Aladar A Microorganisms for preventing and treating neoplasms accompanying cellular therapy
CA2836299A1 (en) 2011-04-15 2012-10-18 Genelux Corporation Clonal strains of attenuated vaccinia viruses and methods of use thereof
US8859256B2 (en) * 2011-10-05 2014-10-14 Genelux Corporation Method for detecting replication or colonization of a biological therapeutic

Also Published As

Publication number Publication date
IL160052A0 (en) 2004-06-20
EP1414994B9 (de) 2008-11-12
ATE452205T1 (de) 2010-01-15
SG168404A1 (en) 2011-02-28
CN1617935A (zh) 2005-05-18
US20090117048A1 (en) 2009-05-07
US20040234455A1 (en) 2004-11-25
MXPA04000882A (es) 2005-06-06
BR0211546A (pt) 2004-07-13
US20090117047A1 (en) 2009-05-07
WO2003014380A2 (en) 2003-02-20
US20090123382A1 (en) 2009-05-14
DE60222910T4 (de) 2009-01-15
EP1281767A2 (de) 2003-02-05
EP1281767A3 (de) 2003-05-28
CA2456055A1 (en) 2003-02-20
US8586022B2 (en) 2013-11-19
NO20040428L (no) 2004-03-31
PL374326A1 (en) 2005-10-17
KR100987574B1 (ko) 2010-10-12
EP1414994A2 (de) 2004-05-06
US8568707B2 (en) 2013-10-29
NZ530818A (en) 2007-07-27
TR200400149T2 (tr) 2005-10-21
KR20100063143A (ko) 2010-06-10
CA2456055C (en) 2012-01-24
DE60234793D1 (de) 2010-01-28
KR20080108600A (ko) 2008-12-15
US20050069491A1 (en) 2005-03-31
RU2357754C2 (ru) 2009-06-10
EP1414994B1 (de) 2007-10-10
RU2004106155A (ru) 2005-07-10
HK1065826A1 (en) 2005-03-04
US20090117049A1 (en) 2009-05-07
US20030059400A1 (en) 2003-03-27
US8642257B2 (en) 2014-02-04
CN100415897C (zh) 2008-09-03
KR20040054668A (ko) 2004-06-25
KR100987598B1 (ko) 2010-10-12
DE60222910D1 (de) 2007-11-22
DE60222910T2 (de) 2008-07-24
WO2003014380A3 (en) 2004-01-22

Similar Documents

Publication Publication Date Title
ATE375401T1 (de) Vaccinia virus für diagnose und behandlung von tumoren
ATE516304T1 (de) Nrg-2 nukleinsäuren, polypeptide und diagnostische / therapeutische methoden
ATE527375T1 (de) Diagnose und behandlung von brustkrebs mit scn5a
DE69933998D1 (de) Verbindungen und verfahren für therapie und diagnose von lungenkrebs
DE60039353D1 (de) Verbindungen und verfahren für therapie und diagnose von lungenkrebs
ATE519857T1 (de) Lichtemittierende mikroorganismen und viren für die diagnose von erkrankungen die mit verletztem oder entzündetem gewebe zusammenhängen
TR200103560T2 (tr) Göğüs kanserinin teşhis ve tedavisi için bileşimler ve bunların kullanımı
ATE364698T1 (de) Neues, physiologisch aktives peptid und dessen verwendung
BR9907259A (pt) Compostos para terapia e diagnóstico de câncer de pulmão e processos para o seu uso
AU6160201A (en) Human polypeptides causing or leading to the killing of cells including lymphoidtumor cells
DK0784703T3 (da) Lamininkæder: Diagnostisk og terapeutisk anvendelse
TR199903154T2 (xx) Meme kanserinin tedavisi ve te�hisi i�in bile�imler ve y�ntemler
PT969877E (pt) Metodos para a modulacao do crescimento de arterias colaterais e/ ou de outras arterias a partir de ligacoes arteriolares pre-existentes
DE60238945D1 (de) Bag3-antikörper zur nutzung in forschung, diagnose und der behandlung von krankheiten, an denen zelltod beteiligt ist
EP1323732A4 (de) Zellkernlokalisierendes protein für beta-catenin
BR0207327A (pt) Amino derivados de biotina e seus conjugados com agentes quelantes macrocìclicos
DE60301891D1 (de) Peptid für die Diagnose und Therapie von Tumoren
DE50214523D1 (de) Nukleotidträger zur diagnose und therapie oraler erkrankungen
EP1914316A3 (de) Mikroorganismen und Zellen zur Diagnose und Behandlung von Tumoren
GB0030050D0 (en) Proteins, genes and their use for diagnosis and treatment of bipolar affective disorder (BAD) and unipolar depression

Legal Events

Date Code Title Description
RER Ceased as to paragraph 5 lit. 3 law introducing patent treaties